- ►prsjournal.com [PDF] N Nigam, J Hedaya, WR Freeman - British Medical Journal, 2008 - bjo.bmj.com LB Cantor Correspondence to: LB Cantor, Department of Ophthalmology, Indiana
University School of Medicine, Indianapolis, IN 46202, USA; lcantor@iupui.edu
Funding: Supported in part by an unrestricted research grant from the ... Related articles - All 5 versions
A Lux, H Llacer, F Heussen, AM Joussen - British Journal of Ophthalmology, 2007 - bjo.bmj.com Methods: Forty-three patients with visual loss due to neovascular age-related
macular disease (ARMD) (44 eyes) underwent intravitreal injections of 1.25 mg
(0.05 ml) bevacizumab and were followed up every 4 weeks for 2, 3 or 6 ... Cited by 10 - Related articles - BL Direct - All 3 versions
- ►prsjournal.com S Bopp - British Journal of Ophthalmology, 2007 - bjo.bmj.com In the era of anti-vascular endothelial growth factor (VEGF) therapy for
exudative age-related macular degeneration (ARMD), a paradigm shift has emerged.
Until then, photodynamic therapy (PDT) was considered a successful ... Cited by 3 - Related articles - BL Direct - All 5 versions
S Hasler, MK Schmid, CN Becht - Klin Monatsbl Augenheilkd, 2008 - thieme-connect.com Hintergrund: Bevacizumab (Avastin®) wird häufig als Off-label-Therapie bei CNV
verwendet. Okuläre Nebenwirkungen sind im klinischen Alltag selten. Wir
berichten über eine akute nichtgranulomatöse anteriore Uveitis nach ... Related articles
A DeWan, MB Bracken, J Hoh - Current opinion in genetics & development, 2007 - Elsevier The discovery of strong associations of the His402 variant of complement factor
H (CFH) and the change in the promoter region of HtrA serine peptidase 1 (HTRA1)
with age-related macular degeneration (AMD) have altered our conception of ... Cited by 10 - Related articles - All 4 versions
JL Prenner, R Kaiser, TS Chang - Ophthalmology, 2009 - Elsevier Anti-vascular endothelial growth factor (VEGF) therapies have fundamentally
changed the treatment of choroidal neovascularization (CNV) secondary to
neovascular age-related macular degeneration (AMD). The results of ANCHOR ( ... Related articles - All 13 versions
- ►prsjournal.com DY Rhee - Evidence-Based Ophthalmology, 2008 - journals.lww.com Research Objective To evaluate fluorescein angiographic and visual acuity (VA)
outcomes from pa- tients enrolled in a trial of a single periocular
corticosteroid injection im- mediately before photodynamic therapy (PDT) ... Related articles - BL Direct - All 2 versions
S de Farmacia - chospab.es El Dr.Juan Lopez Moya, Jefe de Servicio de Oftalmología solicita Lucentis®
(Ranibizumab) como tratamiento de elección en las membranas neovasculares
subretinianas de la Degeneración Macular Asociada a la Edad (DAME) húmeda. Related articles - View as HTML
M Nagpal, K Nagpal, V Mehta - Indian Journal of Ophthalmology, 2009 - pubmedcentral.nih.gov The efficacy of intravitreal anti-vascular endothelial growth factor (VEGF)
agents for treatment of choroidal neovascular membranes (CNVMs) of varying
etiologies as the first line of treatment, has been adequately proven by ... Related articles - All 4 versions
